<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04201899</url>
  </required_header>
  <id_info>
    <org_study_id>CER2019-02343</org_study_id>
    <secondary_id>2019-021-406</secondary_id>
    <nct_id>NCT04201899</nct_id>
  </id_info>
  <brief_title>HYPOPhosphatemia in the Intensive Care: A One-day Point Prevalence Survey</brief_title>
  <acronym>HYPO-P-ICU</acronym>
  <official_title>Hypophosphatemia in the ICU - A One-day Point Prevalence Survey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Society of Intensive Care Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The point prevalence survey aims at defining the until now unknown real prevalence of
      hypophosphatemia (defined as blood phosphate value &lt; 0.8 mmol/l) in international critical
      care settings
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The survey will be conducted on one single day in each centre (D-day), within a week defined
      by the project coordinator (International PI). On D-Day, the local investigators will be
      asked

        1. to complete questions aiming at describing their ICU (number of beds, number of patients
           present on D-Day, type medical/surgical/other, local phosphate reference value, presence
           of an hypophosphatemia treatment protocol in the ICU and route of phosphate delivery in
           case of hypophosphatemia)

        2. to indicate how many patients had a blood phosphate &lt;0.08 mmol/l, for each patient with
           hypophosphatemia, to record the exact lowest value on D-Day, and to record age, number
           of days in ICU on D-Day, presence (or not) of artificial nutrition and continuous renal
           replacement therapy, if any phosphate administration is ongoing Data will be recorded in
           and electronic Case Report Form (e-CRF) in REDCap, and analysed with descriptive
           statistics No outcome data will be recorded (pure point-prevalence) There is no
           intervention
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Prevalence of hypophosphatemia</measure>
    <time_frame>1 day</time_frame>
    <description>Blood value &lt; 0.8 mmol/l</description>
  </primary_outcome>
  <enrollment type="Anticipated">890</enrollment>
  <condition>Critically Ill</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>No intervention - pure observation</intervention_name>
    <description>Phosphate administration (yes or no)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients: adults and children
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: blood phosphate value &lt; 0.8 mmol -

        Exclusion Criteria: Blood phosphate value &gt;0.8 mmol/l

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mette M BERGER, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lausanne University Hospital, Lausanne, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mette M BERGER, MD PhD</last_name>
    <phone>021 3142095</phone>
    <phone_ext>+41</phone_ext>
    <email>Mette.Berger@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samia Abed Maillard, PhD</last_name>
    <phone>079 556 72 68</phone>
    <phone_ext>+41</phone_ext>
    <email>samia.abed-maillard@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>50407</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur 2</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Lausanne University Hospital</name>
      <address>
        <city>Lausanne</city>
        <state>VD</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de Nyon</name>
      <address>
        <city>Nyon</city>
        <zip>1260</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Fumeaux, MD</last_name>
      <phone>022 9946142</phone>
      <phone_ext>+41</phone_ext>
      <email>thierry.fumeaux@ghol.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 14, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Mette M Berger</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Phosphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypophosphatemia</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be collected in central REDCap database. No individual patient data will be made available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

